Ipilimumab
Ipilimumab (Yervoy®) is a monoclonal antibody directed against cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), one of the checkpoints that regulates the immune system. CTLA-4 is a negative regulator of T-cell activation and proliferation, which means that it turns the immune response “off.” Ipilimumab binds to CTLA-4, essentially cutting the brake, thereby enabling the immune system to remain “on” and better attack developing cancers.
Ipilimumab is indicated as a monotherapy for unresectable or metastatic (advanced) melanoma and as an adjuvant treatment of resected stage 3 melanoma.
Provider Resources
